Glaukos Co. (NYSE:GKOS) Shares Bought by Corient Private Wealth LLC

Corient Private Wealth LLC grew its position in Glaukos Co. (NYSE:GKOS) by 1.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,241 shares of the medical instruments supplier’s stock after acquiring an additional 341 shares during the quarter. Corient Private Wealth LLC owned approximately 0.05% of Glaukos worth $4,534,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. IFP Advisors Inc bought a new stake in shares of Glaukos in the 4th quarter valued at approximately $43,000. Asset Planning Inc bought a new stake in shares of Glaukos in the 4th quarter valued at approximately $90,000. Harvest Fund Management Co. Ltd increased its holdings in shares of Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 860 shares during the last quarter. Picton Mahoney Asset Management bought a new stake in shares of Glaukos in the 4th quarter valued at approximately $125,000. Finally, SBI Securities Co. Ltd. bought a new position in Glaukos during the 4th quarter worth $153,000. 99.04% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares in the company, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 6.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on GKOS shares. Piper Sandler restated an “overweight” rating and set a $180.00 price objective (up from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Mizuho upgraded Glaukos from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $140.00 to $200.00 in a research note on Wednesday, February 19th. BTIG Research upped their price objective on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Wells Fargo & Company upped their price objective on Glaukos from $153.00 to $160.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Finally, Stifel Nicolaus upped their price objective on Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, December 31st. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $163.25.

Glaukos Trading Up 1.4 %

Shares of Glaukos stock opened at $102.02 on Friday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The firm has a market cap of $5.77 billion, a price-to-earnings ratio of -35.55 and a beta of 0.99. The business has a fifty day simple moving average of $135.32 and a 200-day simple moving average of $136.53. Glaukos Co. has a fifty-two week low of $87.31 and a fifty-two week high of $163.71.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. On average, equities analysts forecast that Glaukos Co. will post -1.08 EPS for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.